A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors

被引：5
|
作者：
Faulkner, Neil
LoRusso, Patricia M.
Guthrie, Tina
Soria, Jean-Charles
Bahleda, Ratislav
Bendell, Johanna C.
Infante, Jeffrey R.
Massard, Christophe
Van Leeuwen, Barbara
Martini, Jean-Francois
Scheffold, Christian
Burns, Howard A.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163,TARG-09-C197
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C197
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
    Papadopoulos, Kyriakos P.
    Tabernero, Josep
    Markman, Ben
    Patnaik, Amita
    Tolcher, Anthony W.
    Baselga, Jose
    Shi, Weiliang
    Egile, Coumaran
    Ruiz-Soto, Rodrigo
    Laird, A. Douglas
    Miles, Dale
    LoRusso, Patricia M.
    CLINICAL CANCER RESEARCH, 2014, 20 (09) : 2445 - 2456
  • [22] Tumor pharmocokinetics (PK) and pharmocodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study
    Cloughesy, Timothy Francis
    Mischel, Paul S.
    Omuro, Antonio Marcilio Padula
    Prados, Michael
    Wen, Patrick Y.
    Wu, Bin
    Rockich, Kevin
    Xu, Yi
    Lager, Joanne J.
    Mellinghoff, Ingo K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Phase Ib study of the oral PI3Kδ inhibitor linperlisib in patients with advanced solid tumors
    Li, Jin
    Xue, Junli
    Liu, Tianshu
    Feng, Yi
    Xu, Nong
    Huang, Jianjin
    Yin, Yongmei
    Zhang, Jun
    Mou, Haibo
    Shentu, Jiangzhong
    Bao, Hanying
    Xu, Zusheng
    Xu, Zuhong
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (02) : 241 - 251
  • [24] A phase Ib study of the PI3Kδ inhibitor linperlisib in patients with advanced solid tumors.
    Li, Jin
    Xu, Nong
    Liu, Tianshu
    Huang, Jianjin
    Yin, Yongmei
    Mou, Haibo
    Zhang, Jun
    Wu, Lihua
    Liu, Zong Liang
    Bao, Hanying
    Xu, Zusheng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Phase 1, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors
    Patnaik, Amita
    Wood, Debra
    Tolcher, Anthony W.
    Hamilton, Marta
    Kreisberg, Jeffrey I.
    Hammond, Lisa A.
    Schwartz, Garry
    Beeram, Muralidhar
    Hidalgo, Manuel
    Mita, Monica M.
    Wolf, Julie
    Nadler, Paul
    Rowinsky, Eric K.
    CLINICAL CANCER RESEARCH, 2006, 12 (24) : 7406 - 7413
  • [26] Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in patients with advanced solid tumors
    Rasco, D.
    Sullivan, R.
    Lakhani, N.
    Reddy, S.
    Rao, N.
    Denis, L.
    Tolcher, A.
    Flaherty, K. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors
    Papadopoulos, K. P.
    Markman, B.
    Tabernero, J.
    Patnaik, A.
    Heath, E. I.
    DeCillis, A.
    Laird, D.
    Aggarwal, S. K.
    Nguyen, L.
    LoRusso, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.
    Adjei, Alex A.
    Dy, Grace K.
    Zhao, Yujie
    Ma, Wen Wee
    Opyrchal, Mateusz
    Bakhribah, Hatoon
    Jacob, Sandra M.
    O'Hara, Corrie
    Dozier, Askia
    Cmiljanovic, Natasa
    Todaro, Barbara
    Brady, William E.
    Schmitz, Debora
    Dimitrijevic, Sasa
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] A phase 1 PK/PD study of ASN003, a novel, highly selective BRAF and PI3K dual inhibitor, in patients with advanced solid tumors
    Rasco, Drew
    Lakhani, Nehal
    Sullivan, Ryan
    Mita, Monica
    Shah, Jaimini
    Usansky, Helena
    Reddy, Sanjeeva
    Rao, Niranjan
    Denis, Louis J.
    Tolcher, Anthony
    Flaherty, Keith
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [30] A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
    Toshihiko Doi
    Nozomu Fuse
    Takayuki Yoshino
    Takashi Kojima
    Hideaki Bando
    Hideaki Miyamoto
    Masato Kaneko
    Motonobu Osada
    Atsushi Ohtsu
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 89 - 98
12345